Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 12/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 11/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.62 |
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | HRH2 | P25021 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 5/20 | 0.62 |
| ▸ | HRH1 | P35367 | 5/20 | 0.62 |
| ▸ | HTR2A | P28223 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.62 |
| ▸ | HTR1B | P28222 | 3/20 | 0.62 |
| ▸ | HTR2B | P41595 | 3/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | HTR5A | P47898 | 3/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532712 | 0.97 | HTR1A (0.95) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| Eptapirone SCHEMBL8402878 | 0.91 | HTR1A (0.83) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| Eptapirone SCHEMBL8402884 | 0.91 | HTR1A (0.83) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL13532713 | 0.88 | HTR1A (0.78) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL8558871 | 0.86 | HTR1A (0.76) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL15042741 | 0.86 | HTR1A (0.75) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL8402918 | 0.84 | HTR1A (0.71) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL14761726 | 0.83 | HTR1A (0.71) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL15042725 | 0.83 | HTR1A (0.71) | HTR1AADRA1AADRA1BADRA1DADRA2A | |
| SCHEMBL8407259 | 0.83 | HTR1A (0.71) | HTR1AADRA1AADRA1BADRA1DADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4346788-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | Arcadia Medicine, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-0794949-B1 | NOVEL 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS DRUGS | PF MEDICAMENT (FR) | 1998-07-29 | — | — | EP | claimed |
| US-12623070-B2 | Transcutaneous electrical spinal cord neuromodulator and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12565499-B2 | Compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | PSYCHOGENCIS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069339-A1 | TREATMENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER | PSYCHOGENICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040023948-A1 | Fast-dispersing dosage form containing 5-HT1 agonists | CATALENT USA PAINTBALL, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | HTR1A, HTR5A, HTR2A | HTR1A 1/4885ADRA1A 38/4885ADRA1B 43/4885 |
| US-12565499-B2 | Compounds and methods | PSEN1, CHAT, SNCA | HTR1A 53/4885ADRA1A 555/4885ADRA1B 514/4885 |
| US-12623070-B2 | Transcutaneous electrical spinal cord neuromodulator and uses thereof | NCS1, CHRNA10, CHRNA4 | HTR1A 2288/4885ADRA1A 896/4885ADRA1B 730/4885 |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | OPRD1, CRH, HTR2C | HTR1A 79/4885ADRA1A 269/4885ADRA1B 224/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885ADRA1A 95/4885ADRA1B 126/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR1A 486/4885ADRA1A 458/4885ADRA1B 477/4885 |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | HTR2C, SLC6A3, HTR3C | HTR1A 64/4885ADRA1A 360/4885ADRA1B 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.